We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-1.75%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$742M
AUM Growth
+$71.9M
Cap. Flow
+$95.5M
Cap. Flow %
12.87%
Top 10 Hldgs %
60.42%
Holding
166
New
21
Increased
99
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
MPC icon
Marathon Petroleum
MPC
+$23M
2
ETP
Energy Transfer Partners, L.P.
ETP
+$18.5M
3
WPZ
Williams Partners L.P.
WPZ
+$12.3M
4
BPL
Buckeye Partners, L.P.
BPL
+$9.48M
5
EPD icon
Enterprise Products Partners
EPD
+$8.44M

Top Sells

Rank Stock Value
1
OKS
Oneok Partners LP
OKS
+$34.2M
2
PAA icon
Plains All American Pipeline
PAA
+$1.69M
3
CEQP
Crestwood Equity Partners LP
CEQP
+$1.62M
4
MMP
Magellan Midstream Partners, L.P.
MMP
+$1.55M
5
FNCL icon
Fidelity MSCI Financials Index ETF
FNCL
+$1.4M

Sector Composition

Rank Sector Weight
1 Energy 73.54%
2 Healthcare 7.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTMX icon
101
CytomX Therapeutics
CTMX
$705M
$437K 0.06%
24,077
+2,202
+10% +$34.4K
AGIO icon
102
Agios Pharmaceuticals
AGIO
$2.16B
$430K 0.06%
6,435
+588
+10% +$35.3K
IOVA icon
103
Iovance Biotherapeutics
IOVA
$2.23B
$423K 0.06%
54,523
+4,987
+10% +$31.6K
AGEN
104
Agenus
AGEN
$249M
$417K 0.06%
4,816
+441
+10% +$35.7K
LJPC
105
DELISTED
La Jolla Pharmaceutical Company
LJPC
$412K 0.06%
11,845
+1,084
+10% +$34.9K
XLRN
106
DELISTED
Acceleron Pharma
XLRN
$410K 0.06%
10,977
+1,004
+10% +$34.9K
LOXO
107
DELISTED
Loxo Oncology, Inc
LOXO
$407K 0.05%
4,413
+404
+10% +$31.4K
CBIO
108
Crescent Biopharma
CBIO
$602M
$405K 0.05%
290
+27
+10% +$31.7K
BLUE
109
DELISTED
bluebird bio
BLUE
$404K 0.05%
227
+20
+10% +$27.9K
RETA
110
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$402K 0.05%
12,925
+1,182
+10% +$35.5K
CLDX icon
111
Celldex Therapeutics
CLDX
$2.77B
$400K 0.05%
9,318
+852
+10% +$31.9K
CRBP icon
112
Corbus Pharmaceuticals
CRBP
$170M
$400K 0.05%
1,864
+171
+10% +$33.5K
KPTI icon
113
Karyopharm Therapeutics
KPTI
$168M
$393K 0.05%
2,385
+218
+10% +$31.2K
PRTA icon
114
Prothena Corp
PRTA
$458M
$392K 0.05%
6,048
+554
+10% +$33.9K
PTCT icon
115
PTC Therapeutics
PTCT
$6.37B
$392K 0.05%
19,612
+1,794
+10% +$35.1K
PRTK
116
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$370K 0.05%
14,726
+1,347
+10% +$31.4K
GBT
117
DELISTED
Global Blood Therapeutics, Inc.
GBT
$368K 0.05%
11,845
+1,084
+10% +$30.5K
CALA
118
DELISTED
Calithera Biosciences, Inc
CALA
$367K 0.05%
1,166
+107
+10% +$33.8K
XNCR icon
119
Xencor
XNCR
$1.44B
$364K 0.05%
15,881
+1,452
+10% +$32.2K
TCRT icon
120
Alaunos Therapeutics
TCRT
$4.74M
$362K 0.05%
393
+36
+10% +$32K
NVAX icon
121
Novavax
NVAX
$1.23B
$351K 0.05%
15,414
+1,410
+10% +$31.6K
TGTX icon
122
TG Therapeutics
TGTX
$8.58B
$349K 0.05%
29,453
+2,694
+10% +$30.7K
ACHN
123
DELISTED
Achillion Pharmaceuticals
ACHN
$348K 0.05%
77,433
+7,083
+10% +$31.4K
MGNX icon
124
MacroGenics
MGNX
$235M
$341K 0.05%
18,449
+1,688
+10% +$29.2K
CYTK icon
125
Cytokinetics
CYTK
$11B
$339K 0.05%
23,395
+2,140
+10% +$29.2K
3 4
5
6 7

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q3 2017 Portfolio in Review

As of Q3 2017, Virtus ETF Advisers held 166 positions worth $742M, up 11% from $670M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Virtus ETF Advisers deployed $95.5M of net new capital in Q3 2017, opening 21 new positions and adding to 99 existing holdings. Its largest new stake was Direxion Daily Financial Bull 3x ETF: 20,503 shares worth $1.15M.

By sector, the portfolio is most concentrated in Energy at 74% of assets, down from 74% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Plains All American Pipeline, an estimated $1.69M trimmed.

  • Virtus ETF Advisers's largest Q3 2017 buy was Direxion Daily Financial Bull 3x ETF: 20,503 shares worth $1.15M.
  • Virtus ETF Advisers added most to Marathon Petroleum in Q3 2017, an estimated $23M increase.
  • Virtus ETF Advisers's biggest Q3 2017 reduction was Plains All American Pipeline, cutting an estimated $1.69M.
  • Virtus ETF Advisers fully exited Oneok Partners LP in Q3 2017, selling an estimated $34.2M.
  • Virtus ETF Advisers's ten largest holdings make up 60% of its $742M portfolio in Q3 2017.
  • Virtus ETF Advisers opened 21 new positions and closed 7 in Q3 2017.
  • Virtus ETF Advisers's portfolio value rose 11% quarter-over-quarter to $742M.

Based on Virtus ETF Advisers's 13F filing for Q3 2017, filed 14 Nov 2017.